MedTrace Logo

Spatial Repellents for Vector Control

NCT04795648 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1911

Last updated 2024-04-02

No results posted yet for this study

Summary

The primary objective of the study is to demonstrate and quantify the protective efficacy of a single Spatial Repellent (SR) product, in reducing malaria infection in a human cohort. The study design will be a prospective cluster Randomized Control Trial (cRCT).

Conditions

Interventions

DEVICE

Transfluthrin

Passive emanator with formulated transfluthrin

DEVICE

Placebo

Passive emanator with formulated inert ingredients

Sponsors & Collaborators

  • S.C. Johnson & Son, Inc.

    collaborator INDUSTRY

  • fhiClinical

    collaborator UNKNOWN

  • Malaria Research and Training Center, Bamako, Mali

    collaborator OTHER

  • Catholic Relief Services

    collaborator OTHER

  • University of Notre Dame

    lead OTHER

Principal Investigators

  • John P Grieco, Ph.D. · University of Notre Dame

  • Suzanne Van Hulle, M.H.S · Catholic Relief Services

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
10 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-08
Primary Completion
2024-03-02
Completion
2024-03-02

Countries

  • Mali

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04795648 on ClinicalTrials.gov